Business
Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently ...
Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales
About this update from Scilex Holding Company
[{"type":"text","content":"Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information \n PALO ALTO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announces record revenue for the month of August 2023 and is providing certain preliminary unaudited financial results for the month ended August 31, 2023, and year-to-date as of August 31, 2023, based on currently available information. Scilex estimates that: ZTlido gross sales for (i) August 2023 were in the range of $13.0 million to $14.0 million, compared to $10.1 million in August 2022, representing growth in the range of 29% to 39%; and (ii) year-to-date August 2023 were in the range of $87.2 million to $91.3 million, compared to $56.3 million for year-to-date August 2022, representing growth in the range of 55% to 62%.ZTlido net sales for (i) August 2023 were in the range of $4.4 million to $4.8 million, compared to $4.0 million in August 2022, representing growth in the range of 10% to 20%; and (ii) year-to-date August 2023 were in the range of $26.2 million to $32.0 million, compared to $21.3 million for year-to-date August 2022, representing growth in the range of 23% to 50%.Total product gross sales for (i) August 2023 were in the range of $13.4 million to $14.6 million, compared to $10.1 million in August 2022, representing growth in the range of 33% to 44%; and (ii) year-to-date August 2023 were in the range of $89.3 million to $93.7 million, compared to $56.3 million for year-to-date August 2022, representing growth in the range of 59% to 66%.Total product net sales for (i) August 2023 were in the range of $4.5 million to $4.9 million, compared to $4.0 million in August 2022, representing growth in the range of 13% to 23%; and (ii) year-to-date August 2023 were in the range of $26.3 million to $32.2 million, compared to $21.3 million for year-to-date August 2022, representing growth in the range of 2...